Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Early specialised palliative care: interventions, symptoms, problems

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Was amorphous aluminium hydroxyphosphate sulfate adequately evaluated before authorisation in Europe?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

Bidragets oversatte titel基于发病机制治疗遗传性神经发育障碍的未来之路
OriginalsprogEngelsk
TidsskriftClinical Pharmacology and Therapeutics
Vol/bind104
Udgave nummer4
Sider (fra-til)606-609
ISSN0009-9236
DOI
StatusUdgivet - 13 jul. 2018

ID: 54833158